Cocrystal Pharma Develops Novel Ebola Screening Technology Marketwired Cocrystal Pharma, Inc. 3 minutes ago
BOTHELL, WA--(Marketwired - October 23, 2014) - Cocrystal Pharma, Inc. (COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
Cocrystal utilized its core platform technology to develop the in vitro test.
According to Cocrystal Chief Scientist, Dr. Roger Kornberg, "We are very excited to have cloned the gene, purified and characterized its product, and integrated the gene product into our high-throughput platform. We believe we are the first group to have developed a novel screening methodology that can accurately iden
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.